Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 161
Filter
Add more filters

Country/Region as subject
Publication year range
1.
Endocr J ; 71(8): 777-787, 2024 Aug 08.
Article in English | MEDLINE | ID: mdl-38839346

ABSTRACT

Central hypothyroidism and dyslipidemia are well-known adverse events (AEs) of bexarotene therapy. Although hypothyroidism is known to cause dyslipidemia, no study has examined the association between hypothyroidism and dyslipidemia in patients undergoing bexarotene therapy. The aim of this study is to examine this association. A retrospective observational study was performed among 294 patients who initiated bexarotene therapy in Japan (nation-wide postmarketing complete surveillance). Jonckheere-Terpstra (one sided) test was performed to evaluate the effect of the bexarotene dose on lipid metabolisms, and regression analyses were performed to evaluate associations of bexarotene dose, free thyroxine (FT4), body mass index (BMI), and lipid metabolisms. Most patients developed hypothyroidism. Two-third of patients showed FT4 values below the lower limit at 1 week. Triglycerides (TG) increased in a bexarotene dose-dependent manner, and grade ≥3 AEs on hypertriglyceridemia was observed in 39% of the patients. Additionally, one-third of grade ≥3 AEs on hypertriglyceridemia occurred within 1 week. The delta_FT4 (difference in FT4 from baseline) negatively correlated with TG increase at 1 week (p = 0.012) but not with low density lipoprotein cholesterol (LDL-C) increase at any week. Bexarotene-induced hypothyroidism is almost inevitable and occurred quickly. Bexarotene-induced hypertriglyceridemia showed positive bexarotene dose dependency and negative delta_FT4 dependency. Prophylactic and appropriate thyroid hormone compensation therapy and starting bexarotene at low doses with subsequent titration while managing dyslipidemia may have a beneficial effect for the successful continuation of bexarotene therapy without severe endocrine and metabolic AEs.


Subject(s)
Bexarotene , Dyslipidemias , Hypothyroidism , Humans , Bexarotene/adverse effects , Hypothyroidism/chemically induced , Hypothyroidism/epidemiology , Male , Female , Middle Aged , Retrospective Studies , Aged , Dyslipidemias/chemically induced , Japan/epidemiology , Thyroxine/blood , Triglycerides/blood , Adult , Tetrahydronaphthalenes/adverse effects , Tetrahydronaphthalenes/therapeutic use , Aged, 80 and over , Anticarcinogenic Agents/therapeutic use , Anticarcinogenic Agents/adverse effects , Hypertriglyceridemia/chemically induced
2.
Neurosurg Rev ; 47(1): 564, 2024 Sep 07.
Article in English | MEDLINE | ID: mdl-39242404

ABSTRACT

Delayed cerebral ischemia (DCI) is one of the most important outcome determinants for aneurysmal subarachnoid hemorrhage (aSAH). VASOGRADE, which combines World Federation of Neurological Surgeons grade and modified Fisher grade, is a useful scale for predicting DCI after aSAH. However, no studies have investigated whether VASOGRADE influences the treatment options. We retrospectively analyzed 781 aSAH patients who were prospectively enrolled in 9 primary stroke centers from 2013 to 2021. The total cohort consisted of 76 patients (9.7%) with VASOGRADE-Green, 390 patients (49.9%) with VASOGRADE-Yellow, and 315 patients (40.3%) with VASOGRADE-Red. Worse VASOGRADE had higher incidences of DCI, which occurred in 190 patients (24.3%). As only 5 patients (6.6%) with VASOGRADE-Green developed DCI, we searched for DCI-associated factors in patients with VASOGRADEs-Yellow and -Red. Multivariate analyses revealed independent treatment factors suppressing DCI as follows: no postoperative hemorrhagic complication, combined administration of fasudil hydrochloride and cilostazol, combination of clipping and cisternal drainage, and coiling for VASOGRADE-Yellow; and clipping, and administration of fasudil hydrochloride with or without cilostazol for VASOGRADE-Red. The findings suggest that treatment strategies should be determined based on VASOGRADE to prevent DCI after aSAH.


Subject(s)
Brain Ischemia , Subarachnoid Hemorrhage , Humans , Subarachnoid Hemorrhage/complications , Subarachnoid Hemorrhage/surgery , Male , Female , Middle Aged , Brain Ischemia/etiology , Aged , Retrospective Studies , Adult , Cilostazol/therapeutic use , Cohort Studies , Treatment Outcome , Intracranial Aneurysm/surgery , Intracranial Aneurysm/complications , 1-(5-Isoquinolinesulfonyl)-2-Methylpiperazine/analogs & derivatives
3.
Int J Mol Sci ; 25(3)2024 Jan 30.
Article in English | MEDLINE | ID: mdl-38338974

ABSTRACT

Aneurysmal subarachnoid hemorrhage (SAH) has increased with the aging of the population, but the outcome for elderly SAH patients is very poor. Therefore, predicting the outcome is important for determining whether to pursue aggressive treatment. Pigment epithelium-derived factor (PEDF) is a matricellular protein that is induced in the brain, and the plasma levels could be used as a biomarker for the severity of metabolic diseases. This study investigated whether acute-phase plasma PEDF levels could predict outcomes after aneurysmal SAH in the elderly. Plasma samples and clinical variables were collected over 1-3 days, post-SAH, from 56 consecutive elderly SAH patients ≥75 years of age registered in nine regional stroke centers in Japan between September 2013 and December 2016. The samples and variables were analyzed in terms of 3-month outcomes. Acute-phase plasma PEDF levels were significantly elevated in patients with ultimately poor outcomes, and the cutoff value of 12.6 µg/mL differentiated 3-month outcomes with high sensitivity (75.6%) and specificity (80.0%). Acute-phase plasma PEDF levels of ≥12.6 µg/mL were an independent and possibly better predictor of poor outcome than previously reported clinical variables. Acute-phase plasma PEDF levels may serve as the first biomarker to predict 3-month outcomes and to select elderly SAH patients who should be actively treated.


Subject(s)
Serpins , Subarachnoid Hemorrhage , Aged , Humans , Biomarkers , Eye Proteins , Nerve Growth Factors , Serpins/blood , Serpins/chemistry , Subarachnoid Hemorrhage/blood , Subarachnoid Hemorrhage/diagnosis , Treatment Outcome
4.
Inorg Chem ; 62(8): 3506-3517, 2023 Feb 27.
Article in English | MEDLINE | ID: mdl-36787191

ABSTRACT

Doping or ion substitution is often used as an effective strategy to improve photocatalytic activities of several semiconductors. Most frequently, the dopants provide extra states to increase light absorption, alter the electronic structure, or lower the carrier recombination. This work focuses on ion substitution in Bi2WO6, where the dopants modify band-edge potentials of the catalysts. Specifically, we investigate how the electronegativity (EN) of the dopant could be used to tune the band-edge potentials and how such changes influence the photocatalytic mechanism. Compared to Te that has a lower EN, I lowers the band-edge potentials. While substitutions with both ions enhance Rh B photodegradation and benzylamine photooxidation, the modified band potentials of I-doped Bi2WO6 influence the benzylamine photooxidation pathway, resulting in higher selectivity. Additionally, substitution of I7+ in the Bi2WO6 lattice improves the morphologies, decreases the band-gap energy, and reduces the carrier recombination. As a result, I-doped Bi2WO6 shows almost 3 times higher %conversion while maintaining 100% selectivity in the oxidative coupling of benzylamine. The findings here signify the importance of the choices of dopants on the photocatalytic reactions and would benefit the design of other related materials for such applications.

5.
J Immunol ; 206(7): 1469-1477, 2021 04 01.
Article in English | MEDLINE | ID: mdl-33648938

ABSTRACT

Leucine-rich α-2 glycoprotein (LRG), one of the acute phase proteins mainly produced by the liver, similar to C-reactive protein, has been recognized as an inflammatory biomarker for rheumatoid arthritis and inflammatory bowel diseases. We recently demonstrated that LRG was also increased in the sera of psoriasis patients and correlated well with disease activity with a sensitivity and specificity much higher than C-reactive protein; however, whether LRG mechanistically contributed to the pathogenesis of psoriasis remained unclear. In this study, we explored the role of LRG in psoriasiform inflammation using LRG-knockout (KO) mice in an imiquimod (IMQ)-mediated model. Following topical treatment with IMQ, serum levels of LRG and its expression in the liver were abruptly elevated. Similarly, an acute surge of proinflammatory cytokines was observed in the liver, including IL-1ß, TNF-α, and IL-6, although LRG-KO mice showed delayed responses. LRG-KO mice showed less skin inflammation in the IMQ model than wild-type mice. K5.Stat3C mice developed psoriasis-like lesions following tape stripping, which also abruptly induced LRG expression in the liver. A deficiency of Lrg mitigated tape stripping-induced lesions, similar to the IMQ model. These results indicate that LRG modulates both feed-forward and feedback loops of cytokines in the skin-liver axis involved with psoriasiform inflammation.


Subject(s)
Biomarkers/metabolism , Glycoproteins/metabolism , Liver/metabolism , Psoriasis/immunology , Skin/metabolism , Animals , Cytokines/metabolism , Disease Models, Animal , Glycoproteins/genetics , Humans , Imiquimod , Inflammation Mediators/metabolism , Liver/pathology , Mice , Mice, Inbred C57BL , Mice, Knockout , Skin/pathology , Up-Regulation
6.
Acta Neurochir (Wien) ; 165(12): 3637-3641, 2023 Dec.
Article in English | MEDLINE | ID: mdl-37932634

ABSTRACT

Tyrosine kinase inhibitors (TKIs) have been widely used to treat chronic myeloid leukemia. Nilotinib and ponatinib, which are second- and third-generation TKIs, have been reported to cause cerebrovascular arterial complications. Here, we present two cases of moyamoya disease presenting with symptomatic ischemic stroke during new-generation TKI treatment. We judged that new-generation TKI treatment was a factor in symptomatic ischemic stroke of unknown moyamoya disease in both cases. Noninvasive examinations using magnetic resonance imaging or carotid ultrasonography should be performed before and during new-generation TKI treatment in order to prevent symptomatic ischemic stroke.


Subject(s)
Antineoplastic Agents , Ischemic Stroke , Moyamoya Disease , Humans , Moyamoya Disease/chemically induced , Moyamoya Disease/diagnostic imaging , Moyamoya Disease/drug therapy , Protein Kinase Inhibitors/adverse effects
7.
Int J Mol Sci ; 23(23)2022 Dec 02.
Article in English | MEDLINE | ID: mdl-36499510

ABSTRACT

Aneurysmal subarachnoid hemorrhage (SAH) is a poor-outcome disease with a delayed neurological exacerbation. Fibulin-5 (FBLN5) is one of matricellular proteins, some of which have been involved in SAH pathologies. However, no study has investigated FBLN5's roles in SAH. This study was aimed at examining the relationships between serially measured plasma FBLN5 levels and neurovascular events or outcomes in 204 consecutive aneurysmal SAH patients, including 77 patients (37.7%) with poor outcomes (90-day modified Rankin Scale 3-6). Plasma FBLN5 levels were not related to angiographic vasospasm, delayed cerebral ischemia, and delayed cerebral infarction, but elevated levels were associated with severe admission clinical grades, any neurological exacerbation and poor outcomes. Receiver-operating characteristic curves indicated that the most reasonable cut-off values of plasma FBLN5, in order to differentiate 90-day poor from good outcomes, were obtained from analyses at days 4-6 for all patients (487.2 ng/mL; specificity, 61.4%; and sensitivity, 62.3%) and from analyses at days 7-9 for only non-severe patient (476.8 ng/mL; specificity, 66.0%; and sensitivity, 77.8%). Multivariate analyses revealed that the plasma FBLN5 levels were independent determinants of the 90-day poor outcomes in both all patients' and non-severe patients' analyses. These findings suggest that the delayed elevation of plasma FBLN5 is related to poor outcomes, and that FBLN5 may be a new molecular target to reveal a post-SAH pathophysiology.


Subject(s)
Brain Ischemia , Subarachnoid Hemorrhage , Vasospasm, Intracranial , Humans , Subarachnoid Hemorrhage/complications , Brain Ischemia/complications , Cerebral Infarction/complications , ROC Curve , Vasospasm, Intracranial/complications
8.
Mod Rheumatol ; 31(6): 1120-1128, 2021 Nov.
Article in English | MEDLINE | ID: mdl-33535851

ABSTRACT

OBJECTIVE: Systemc sclerosis (SSc) is an autoimmune disorder characterized by fibrosis of the skin and internal organs. Recently, it has been shown that leucine-rich α-2 glycoprotein (LRG) functions as a modulator of transforming growth factor-ß (TGF-ß) signaling in fibrosis. We aimed to characterize the effect of LRG in SSc model and SSc patients. METHODS: Histological analysis was performed on LRG knockout (KO) and wild type (WT) mouse in the skin and the lung after bleomycin administration. Serum LRG levels were measured during the injection period. Gene expression analysis of the skin and lung tissue from LRG KO and WT mice was performed. In addition, serum LRG levels were determined in SSc patients and healthy controls. RESULTS: LRG KO mice display an inhibition of fibrosis in the skin in association with a decrease of dermal thickness, collagen deposition, and phospho-Smad3 expression after bleomycin. Serum LRG concentration significantly increased in WT mice after bleomycin. There was also a suppression of inflammation and fibrosis in the LRG KO mouse lung indicated by a reduction of lung weight, collagen content, and phospho-Smad3 expression after bleomycin. Gene expressions of TGF-ß and Smad2/3 were significantly reduced in LRG KO mice. Serum LRG levels in SSc patients were significantly higher than those in controls. CONCLUSION: LRG promotes fibrotic processes in SSc model through TGF-ß-Smad3 signaling, and LRG can be a biomarker for SSc in humans and also a potential therapeutic target for SSc.


Subject(s)
Glycoproteins , Pulmonary Fibrosis , Scleroderma, Systemic , Animals , Bleomycin , Disease Models, Animal , Fibroblasts , Fibrosis , Glycoproteins/genetics , Humans , Mice , Pulmonary Fibrosis/chemically induced , Scleroderma, Systemic/chemically induced , Scleroderma, Systemic/genetics , Scleroderma, Systemic/pathology , Skin/pathology , Transforming Growth Factor beta
9.
Circ J ; 84(12): 2302-2311, 2020 11 25.
Article in English | MEDLINE | ID: mdl-33071243

ABSTRACT

BACKGROUND: Lead-induced tricuspid regurgitation (TR) after cardiac implantable electronic device (CIED) implantation is not fully understood. This study aimed to reveal the features of lead-induced TR by 3-dimensional echocardiography (3DE) in patients with heart failure (HF) events after CIED implantation.Methods and Results:In 143 patients, 3DE assessments for the tricuspid valve (TV) and right ventricular morphologies were sequentially performed within 3 days after CIED implantations, during TR exacerbations, and at ≥6 months after TR exacerbations. TR exacerbations were observed in 29 patients (median 10 months after CIED implantation, range 1-28 months), 15 of whom had lead-induced TR. In the 29 patients, the tenting height of the TV, tricuspid annular (TA) height, and TA area at baseline were independent predictors for worsening TR. In patients with lead-induced TR, tenting height of the TV and TA area were identified as the risk factors. In addition, all patients with a lead positioned on a leaflet immediately after CIED implantations developed lead-induced TR. At follow up, TR exacerbation of lead-induced TR persisted with TA remodeling, but it was improved in the lead non-related-TR group. CONCLUSIONS: TA remodeling at baseline and a lead location on a leaflet immediately after CIED implantation were associated with lead-induced TR in patients with HF events after CIED implantation. Persistent TA remodeling may make lead-induced TR refractory against HF treatments.


Subject(s)
Defibrillators, Implantable/adverse effects , Echocardiography, Three-Dimensional , Heart Failure , Pacemaker, Artificial/adverse effects , Tricuspid Valve Insufficiency , Electronics , Heart Failure/diagnostic imaging , Heart Failure/etiology , Humans , Retrospective Studies , Treatment Outcome , Tricuspid Valve Insufficiency/diagnostic imaging , Tricuspid Valve Insufficiency/etiology
10.
Jpn J Clin Oncol ; 50(12): 1419-1425, 2020 Dec 16.
Article in English | MEDLINE | ID: mdl-32676637

ABSTRACT

OBJECTIVE: Onco-cardiology services are expanding rapidly in Japan. To provide a better service, it is important to consider the needs of oncologists. However, little is known regarding specific needs for which oncologists should consult cardiologists to manage cardiovascular problems of their patients. We analysed cardiology consultations sought by oncologists to evaluate the role of cardiologists in cancer treatment. METHOD: We retrospectively investigated consecutive 2064 cardiology consultations of cancer patients in the University of Tsukuba Hospital, Tsukuba, Japan, between January 2014 and December 2018. RESULTS: The most common timing of cardiology consultation was before the commencement of cancer treatment (n = 1355; 65.7%), followed by after the commencement of cancer treatment (n = 686; 33.2%). Among the 361 consultations before the administration of anticancer drugs, 235 (65.1%) were for anthracycline-based regimens. There were 506 (24.5%) consultations for the management of cardiovascular emergencies developing after the commencement of cancer treatment; venous thromboembolism was the most frequent (n = 125; 24.7%), followed by atrial fibrillation (n = 110; 21.7%) and heart failure (n = 74; 14.6%). There were marked differences in the types of cardiovascular emergencies depending on the type of cancer. CONCLUSIONS: This survey revealed the various cardiovascular problems for which oncologists sought interventions by cardiologists. A multidisciplinary approach in an onco-cardiology service is essential to achieve optimal long-term outcomes.


Subject(s)
Cardiology , Medical Oncology/statistics & numerical data , Referral and Consultation , Adolescent , Adult , Aged , Aged, 80 and over , Antineoplastic Agents/adverse effects , Antineoplastic Agents/therapeutic use , Cardiovascular Diseases/complications , Cardiovascular Diseases/therapy , Child , Female , Humans , Japan , Male , Medical Oncology/trends , Middle Aged , Neoplasms/complications , Neoplasms/therapy , Retrospective Studies , Surveys and Questionnaires , Young Adult
12.
Clin Immunol ; 193: 123-130, 2018 08.
Article in English | MEDLINE | ID: mdl-29162406

ABSTRACT

Neuropsychiatric systemic lupus erythematosus (NPSLE) is often difficult to diagnose and distinguish from other diseases, because no NPSLE-specific antibodies have been identified. We developed a novel proteomic strategy for identifying and profiling antigens in immune complexes in the cerebrospinal fluid (CSF), and applied this strategy to 26 NPSLE patients. As controls, we also included 25 SLE patients without neuropsychiatric manifestations (SLE), 15 with relapsing remitting multiple sclerosis (MS) and 10 with normal pressure hydrocephalus (NPH). We identified immune complexes of suprabasin (SBSN) in the CSF of the NPSLE group. The titer of anti-SBSN antibodies was significantly higher in the CSF of the NPSLE group compared to those of the SLE, MS and NPH groups. Microarray data showed that the senescence and autophagy pathways were significantly changed in astrocytes exposed to anti-SBSN antibodies. Our findings indicate that SBSN could be a novel autoantibody for the evaluation of suspected NPSLE.


Subject(s)
Antigen-Antibody Complex/cerebrospinal fluid , Antigens, Differentiation/metabolism , Astrocytes/physiology , Autoantibodies/cerebrospinal fluid , Autoantigens/immunology , Lupus Erythematosus, Systemic/diagnosis , Lupus Vasculitis, Central Nervous System/diagnosis , Neoplasm Proteins/metabolism , Adult , Antigens, Differentiation/immunology , Autoantigens/metabolism , Autophagy , Cells, Cultured , Cellular Senescence , Diagnosis, Differential , Female , Humans , Male , Middle Aged , Neoplasm Proteins/immunology , Proteomics , Signal Transduction
13.
Cerebrovasc Dis ; 46(5-6): 242-248, 2018.
Article in English | MEDLINE | ID: mdl-30602147

ABSTRACT

OBJECT: We investigated possible associations among the presence of cholesterol crystals in embolic debris, the proportions of debris components, and postoperative cerebral embolism in patients undergoing carotid artery stenting (CAS). METHODS: Sixty-seven consecutive procedures were performed for internal carotid artery stenosis with CAS at our hospital between November 2015 and February 2018. Procedures for emergency CAS for stroke in evolution or crescendo transient ischemic attack were excluded (n = 12). The embolic debris from remaining procedures (n = 55) was stained with hematoxylin-eosin and the red blood cells, white blood cells, and fibrin were quantified by color-based segmentation. Cholesterol crystals and calcification were examined histopathologically. Diffusion-weighted imaging (DWI) was performed 1-3 days after CAS, and the images were used to classify procedures according to the presence of new lesions. RESULTS: Of the 55 CAS procedures, new DWI lesions were identified after 32. One patient had symptomatic cerebral embolism. Higher proportions of patients with cholesterol crystals in embolic debris (17 vs. 78%, p < 0.001) and higher proportion of white blood cells (mean 2.3 [0-9.9] vs. 4.2% [0-29.9%], p < 0.01) were observed in the embolic debris of procedures with and without new DWI lesions. CONCLUSIONS: Cholesterol crystals were common in the embolic debris from patients with postoperative ischemic lesions after CAS. These results suggest that inflammatory destabilization of the intraplaque lipid component is related to postprocedural DWI lesions.


Subject(s)
Carotid Artery, Internal , Carotid Stenosis/therapy , Cholesterol/analysis , Embolic Protection Devices , Endovascular Procedures/adverse effects , Endovascular Procedures/instrumentation , Intracranial Embolism/etiology , Plaque, Atherosclerotic , Stents , Aged , Aged, 80 and over , Carotid Artery, Internal/diagnostic imaging , Carotid Artery, Internal/pathology , Carotid Stenosis/complications , Carotid Stenosis/diagnostic imaging , Carotid Stenosis/pathology , Crystallization , Diffusion Magnetic Resonance Imaging , Female , Humans , Intracranial Embolism/diagnostic imaging , Intracranial Embolism/pathology , Male , Risk Factors , Time Factors , Treatment Outcome
17.
Mod Rheumatol ; 26(3): 384-90, 2016.
Article in English | MEDLINE | ID: mdl-26375433

ABSTRACT

OBJECTIVE: To investigate whether aquaporins (AQPs) are involved in salivary gland dysfunction in patients with neuromyelitis optica (NMO) complicated with Sjögren's syndrome (SS). METHODS: Eight primary SS (pSS) patients, four NMO spectrum disorder (NMOsd) patients complicated with SS (NMOsd-SS), and three control subjects were enrolled. Immunohistochemistry of labial salivary glands (LSGs) was performed to determine the expressions of AQP4, AQP5, and tumor necrosis factor-alpha (TNF-α). In vitro expression of AQP5 was examined by Western blotting in cultured primary salivary gland epithelial cells (SGECs). RESULTS: No expression of AQP4 was shown in all LSGs. AQP5 was clearly expressed in the all acini, but the predominant localization of AQP5 in the apical side was diminished in the patients with pSS or NMOsd-SS compared with the controls and tended to be even lower in NMOsd-SS than pSS. The abnormal localization of AQP5 was associated with poor saliva secretion. No difference was found in TNF-α expression in the LSGs between patients with pSS and NMOsd-SS. AQP5 expression of SGECs in vitro was not changed by TNF-α or interleukin-10. CONCLUSIONS: Our results suggest that AQP5 but not AQP4 contributes to salivary secretion in patients with SS including those with NMO complicated with SS.


Subject(s)
Aquaporin 5/metabolism , Neuromyelitis Optica/metabolism , Saliva/metabolism , Salivary Glands, Minor/metabolism , Sjogren's Syndrome/metabolism , Adult , Aged , Aquaporin 4/metabolism , Epithelial Cells/drug effects , Epithelial Cells/metabolism , Female , Humans , Immunohistochemistry , Interleukin-10/pharmacology , Male , Middle Aged , Neuromyelitis Optica/complications , Neuromyelitis Optica/pathology , Salivary Glands, Minor/drug effects , Salivary Glands, Minor/pathology , Sjogren's Syndrome/complications , Sjogren's Syndrome/pathology , Tumor Necrosis Factor-alpha/metabolism , Tumor Necrosis Factor-alpha/pharmacology
18.
Clin Immunol ; 157(2): 114-20, 2015 Apr.
Article in English | MEDLINE | ID: mdl-25656641

ABSTRACT

Neuropsychiatric systemic lupus erythematosus (NPSLE) is a serious complication in SLE. Although the mechanism of NPSLE remains unclear, cytokines and chemokines are considered to be involved in their pathogenesis. Here we used Bio-Plex Pro assays to examine 27 types of cytokines and chemokines in the cerebrospinal fluid (CSF) of 32 NPSLE patients. We used the CSF of 20 patients with multiple sclerosis (MS) and 22 patients with neuromyelitis optica (NMO) as a disease control group. Fourteen of 27 cytokines/chemokines were significantly higher in the NPSLE patients compared to the MS/NMO patients. We could identify six "minimum predictive markers" by using a weighted-voting algorithm that could distinguish NPSLE from MS and NMO: interleukin (IL)-17, IL-2, interferon (IFN)-γ, IL-5, basic fibroblast growth factor (FGF)-basic and IL-15. The determination of various types of CSF cytokine profiles may contribute to the diagnosis of NPSLE and may help elucidate the mechanisms underlying this disease.


Subject(s)
Cytokines/cerebrospinal fluid , Lupus Vasculitis, Central Nervous System/cerebrospinal fluid , Multiple Sclerosis/cerebrospinal fluid , Neuromyelitis Optica/cerebrospinal fluid , Adolescent , Adult , Algorithms , Case-Control Studies , Diagnosis, Differential , Female , Fibroblast Growth Factor 2/cerebrospinal fluid , Humans , Interferon-gamma/cerebrospinal fluid , Interleukin-15/cerebrospinal fluid , Interleukin-17/cerebrospinal fluid , Interleukin-2/cerebrospinal fluid , Interleukin-5/cerebrospinal fluid , Lupus Vasculitis, Central Nervous System/diagnosis , Lupus Vasculitis, Central Nervous System/immunology , Male , Middle Aged , Multiple Sclerosis/diagnosis , Multiple Sclerosis/immunology , Neuromyelitis Optica/diagnosis , Neuromyelitis Optica/immunology , Sensitivity and Specificity , Young Adult
19.
J Gen Virol ; 95(Pt 1): 135-141, 2014 Jan.
Article in English | MEDLINE | ID: mdl-24108141

ABSTRACT

Most Merkel cell polyomavirus (MCPyV) gene sequences have been reported from Western countries and few data are available for the virus sequences from other geographical areas, especially Asia. Thus, we performed phylogenetic analyses based on the nucleotide sequences of the full-length large T-antigen (LT) and viral protein 1 (VP1) genes derived from a variety of cancers in Japanese patients and compared them with sequences from Caucasians. The LT and VP1 gene-based phylogenetic trees identified two main genetic clades. One clade comprised strains isolated from Caucasians, whereas all of the Japanese tumour-derived MCPyV strains belonged to another clade. These findings confirm that most of the MCPyV strains present in Japan form a clade, distinct from Caucasian strains.


Subject(s)
Antigens, Viral, Tumor/genetics , Capsid Proteins/genetics , Carcinoma, Squamous Cell/virology , Merkel cell polyomavirus/genetics , Phylogeny , Polyomavirus Infections/virology , Tumor Virus Infections/virology , Base Sequence , Humans , Japan , Merkel cell polyomavirus/classification , Merkel cell polyomavirus/isolation & purification , Molecular Sequence Data
20.
Childs Nerv Syst ; 30(9): 1607-11, 2014 Sep.
Article in English | MEDLINE | ID: mdl-24845229

ABSTRACT

BACKGROUND: Spinal arteriovenous metameric syndrome (SAMS) is a combination of more than two separate vascular malformations in the same embryonic metameres. This syndrome, also known as Cobb syndrome, is rare, especially in the neonate. CASE DESCRIPTION: A neonatal girl with a birthmark in the occipital and posterior nuchal regions presented with severe heart failure on the day of birth. The large arteriovenous fistulas in the left hypoglossal canal and in the posterior nuchal region were embolized with detachable coils on the postnatal days 5 and 18, which improved heart failure markedly. The associated intramuscular arteriovenous malformation in the posterior neck was left untreated because large arteriovenous fistulas had been occluded. She grew up without any neurological deficits and developed with normal milestones until the latest follow-up of 8 years old. CONCLUSION: To our knowledge, this is the first case with SAMS in a neonate presenting with congestive heart failure. Presence of a birthmark in a neonate presenting with congestive heart failure may suggest the possible underlying high-flow vascular malformations in the same metamere.


Subject(s)
Arteriovenous Malformations/complications , Arteriovenous Malformations/therapy , Central Nervous System Vascular Malformations/complications , Heart Failure/complications , Female , Humans , Infant, Newborn , Longitudinal Studies , Tomography Scanners, X-Ray Computed
SELECTION OF CITATIONS
SEARCH DETAIL